KEGG   DRUG: Pabinafusp alfa
Entry
D11812                      Drug                                   

Name
Pabinafusp alfa (genetical recombination) (JAN);
Pabinafusp alfa (INN);
Izcargo (TN)
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGESLKI SCKGSGYSFT NYWLGWVRQM PGKGLEWMGD IYPGGDYPTY
SEKFKVQVTI SADKSISTAY LQWSSLKASD TAMYYCARSG NYDEVAYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGKGS SETQANSTTD ALNVLLIIVD DLRPSLGCYG
DKLVRSPNID QLASHSLLFQ NAFAQQAVCA PSRVSFLTGR RPDTTRLYDF NSYWRVHAGN
FSTIPQYFKE NGYVTMSVGK VFHPGISSNH TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD
GELHANLLCP VDVLDVPEGT LPDKQSTEQA IQLLEKMKTS ASPFFLAVGY HKPHIPFRYP
KEFQKLYPLE NITLAPDPEV PDGLPPVAYN PWMDIRQRED VQALNISVPY GPIPVDFQRK
IRQSYFASVS YLDTQVGRLL SALDDLQLAN STIIAFTSDH GWALGEHGEW AKYSNFDVAT
HVPLIFYVPG RTASLPEAGE KLFPYLDPFD SASQLMEPGR QSMDLVELVS LFPTLAGLAG
LQVPPRCPVP SFHVELCREG KNLLKHFRFR DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW
NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF NPDEFLANFS DIHAGELYFV DSDPLQDHNM
YNDSQGGDLF QLLMP
(Light chain)
DIVMTQTPLS LSVTPGQPAS ISCRSSQSLV HSNGNTYLHW YLQKPGQSPQ LLIYKVSNRF
SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP WTFGQGTKVE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H145-H201, H221-L219, H227-H'227, H230-H'230, H262-H322, H368-H426, H596-H609, H847-H857, H'22-H'96, H'145-H'201, H'221-L'219, H'262-H'322, H'368-H'426, H'596-H'609, H'847-H'857, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  Type
Peptide
Remark
Therapeutic category: 3959
Product: D11812<JP>
Efficacy
Fusion protein
Comment
fusion protein/ antibody
Target
IDS [HSA:3423] [KO:K01136]
TFRC (CD71) [HSA:7037] [KO:K06503]
  Pathway
hsa00531  Glycosaminoglycan degradation
hsa04066  HIF-1 signaling pathway
hsa04142  Lysosome
hsa04144  Endocytosis
hsa04145  Phagosome
hsa04216  Ferroptosis
hsa04640  Hematopoietic cell lineage
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   395  Enzyme preparations
    3959  Others
     D11812  Pabinafusp alfa (genetical recombination) (JAN); Pabinafusp alfa (INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    TFRC (CD71)
     D11812  Pabinafusp alfa (genetical recombination) (JAN) <JP>
 Enzymes
  Hydrolases (EC3)
   Sulfatases
    IDS
     D11812  Pabinafusp alfa (genetical recombination) (JAN) <JP>
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11812
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11812
Other DBs
CAS: 2140211-48-7
PubChem: 405226677
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system